Mynosys Cellular Devices said today that it raised $25 million for its Zepto cataract device and named ex-Tear Film Innovations chief Rob Thornhill to be its new CEO.

Fremont, Calif.-based Mynosys said the new funding round, led by Decheng Capital, is earmarked for growing its U.S. commercial footprint, R&D, manufacturing and commercial organization. Decheng’s Dr. Nick Pliam and Wei Xu are slated to join the company’s board in connection with the financing.

Thornhill, who helped found Tear Film, led that company until its 2018 acquisition by then-Novartis (NYSE:NVS) unit Alcon (NYSE:ALC).

“I am excited to work with the Zepto team to deliver on the promise this device brings to cataract surgery,” Thornhill said in prepared remarks. “It is gratifying that Decheng Capital appreciates the tremendous value and potential of the Zepto technology, which has already captured the support of some of the world’s most prominent ophthalmic surgeons. It will be an honor to work with those thought leaders to build on the early success of the device.”

“Zepto is an innovative capsulotomy technology that can affordably be a part of everyone’s surgical armamentarium,” added ophthalmologist Dr. David Chang. “Expanding the Mynosys sales and training staff should increase global access to this device, particularly in practices where a less expensive method of automating the capsulotomy is desirable.”

“For my cataract practice, the Zepto takes capsulotomy centration and strength to a new level, while increasing efficiency in my operating routine. With Rob at the helm, I know we will continue to see innovation and dedicated support from the company,” Dr. Vance Thompson, of the University of South Dakota School of Medicine, said in a press release.